Chemomab Therapeutics (CMMB) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Chemomab Therapeutics reported promising results from its Phase 2 SPRING trial for CM-101, a potential treatment for primary sclerosing cholangitis, driving investor interest and strategic partnership discussions. The company secured $10 million in private placement funding, extending its cash runway to early 2026. Chemomab plans to advance CM-101 to a Phase 3 trial in late 2025, aiming to further capitalize on its promising pipeline.
For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.
